Clinical Trial Update: Administration of the SGLT-2 Inhibitor Dapagliflozin in the Patients With Amyloid Cardiomyopathy [NA]

View source ↗

Summary

A completed clinical trial evaluating the SGLT-2 inhibitor dapagliflozin in patients with amyloid cardiomyopathy across heart failure phenotypes, including redu…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Amyloid Cardiomyopathy
• Heart Failure with Mid-range Ejection Fraction
• Heart Failure with Preserved Ejection Fraction
• Heart Failure with Reduced Ejection Fraction

Drugs mentioned

• FARXIGA (dapagliflozin)

Snippet

Sponsor: National Medical Research Center for Cardiology, Ministry of Health of Russian Federation | Conditions: Heart Failure With Reduced Ejection Fraction, Heart Failure With Preserved Ejection Fraction | NA | Status: COMPLETED